February 6, 2026 – Palo Alto, CA – Leading GMP cell therapy CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that it has successfully generated human induced pluripotent stem (iPS) cells from NKT cells and has begun offering them for research use. NKT cells are immune cells known to possess characteristics of both innate and adaptive immunity and to play important roles in cancer, infectious diseases, autoimmune disorders, and other conditions. The establishment of iPS cells derived from NKT cells is expected to significantly advance research in regenerative medicine and cancer therapy based on immune mechanisms. [Read more…]
Strategies for the Future of CAR-T Therapy Development in 2026 and Beyond
Until the first FDA approval of cancer immunotherapy in 1990, the foundations of cancer treatment were surgery, chemotherapy, radiation therapy, and bone marrow transplantation. For more than a decade, immunotherapy has gained worldwide acceptance as the “fifth pillar” of cancer treatment.
Immunotherapy enlists and strengthens the power of a patient’s immune system to attack and kill the cancer cells. Within the human body, T cells are a type of white blood cell that support immunity. There are 25 million to 1 billion different types of T cells within the human body. These cells fight against anything foreign that enters the human body. [Read more…]
Top iPSC Providers Transforming Preclinical Safety for Big Pharma
The pharmaceutical industry continues to grapple with preclinical and clinical safety issues, with toxicity remaining a leading cause of drug failure. Cardiovascular toxicity, in particular, stands out, accounting for approximately 40% of all drug withdrawals due to safety concerns. To mitigate these risks, human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) have emerged as a critical tool for evaluating cardiac safety. Traditionally, most studies have relied on iPSC-CMs from one or two healthy donors, limiting the representation of broader population variability in drug response. [Read more…]
10 Remarkable Benefits of MSCs That Make Them Exceptional
MSCs are advantageous over other cell types for a variety of reasons. First, they avoid the ethical issues that surround embryonic stem cell research.
Second, repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogeneic transplantation. MSCs reduce both the risks of rejection and complications of transplantation. [Read more…]
5 Questions to Ask Your Doctor about Stem Cell Treatments
Stem cell research is a multi-billion dollar industry. The National Institutes of Health (NIH) allocated over $2 billion per year for stem cell research in the U.S. Additionally, more than a million people around the world have been treated with stem cell therapies.
Growth of stem cell therapeutics has followed in sync with other many types of advanced therapies, including cellular therapies, gene therapies, exosomes, peptide therapeutics, and more. [Read more…]
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 334
- Next Page »